• Magnetic Nano-Antibody CAR-T Mimics for Solid Tumors

  2026-08-13

  The reference study introduces a magnetic bispecific nano-antibody that engages endogenous T cells in vivo and guides the resulting CAR-T-mimicking cells toward PDL1-positive solid tumors. Its combination of CD3-mediated T-cell activation, PDL1-directed recognition, and external magnetic navigation offers a non-genetic strategy for improving tumor infiltration, while also highlighting important translational questions about biodistribution, safety, and immune exhaustion.

• JNJ-26854165 (Serdemetan): Assay Guide

  2026-08-12

  A scenario-based guide to using JNJ-26854165 (Serdemetan), SKU A4204, in cell viability, proliferation, apoptosis, and radiosensitization workflows. It explains solvent handling, endpoint selection, p53-context controls, data interpretation, and practical criteria for selecting a documented research reagent.

• QSHXO in MASLD: Autophagy and Ferroptosis

  2026-08-12

  A 2026 World Journal of Hepatology study identifies coordinated autophagy activation and ferroptosis inhibition as a mechanistic basis for the protective effects of Qushi Huoxue ointment in a mouse model of metabolic associated steatotic liver disease. Its integrated use of histology, biochemical testing, serum component profiling, network pharmacology, molecular validation, and ultrastructural imaging provides a useful framework for interpreting multi-pathway interventions in MASLD.

• Ro 3306: Selective CDK1 Inhibitor for G2/M Arrest

  2026-08-11

  Ro 3306 is an ATP-competitive CDK1 inhibitor used for cell cycle G2/M phase arrest, cancer cell synchronization, and DNA repair mechanism study. Its biochemical activity, formulation limits, and relationship to checkpoint-controlled mitotic entry support phase-resolved experimental design.

• Firefly Luciferase mRNA as an LNP Assay Standard

  2026-08-10

  Firefly Luciferase mRNA can function as more than a reporter: it can help separate payload translation from lipid nanoparticle delivery effects. This guide examines how Cap1, 5-moUTP, poly(A) design, and formulation variables support rigorous mRNA assay development.

• Nicotine Signaling and CKD Progression: Evidence

  2026-08-09

  The reference review synthesizes clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. Its main practical value is a mechanistic framework for separating nicotine-driven renal injury from the broader effects of cigarette smoke and for designing better translational studies.

• Ibuprofen Workflows for Translational Cell Research

  2026-08-08

  Build reproducible Ibuprofen experiments around COX-1 and COX-2 inhibition, apoptosis, and cell-cycle analysis rather than relying on a single viability endpoint. This guide combines practical cell-based workflows with a protein-binding assay framework inspired by modern drug–albumin research, while clearly separating established evidence from proposed starting conditions.

• GSK621: Practical AMPK Activation Workflows

  2026-08-07

  GSK621 is a potent AMPK agonist for connecting energy sensing with autophagy, lipid metabolism, and leukemia-cell responses. This guide translates its signaling profile into reproducible AML assays and a carefully bounded immunometabolic workflow inspired by recent tumor-associated macrophage research.

• Vitamin C (CAS 50-81-7): Reliable Solutions for Cell Assays

  2026-08-07

  This article addresses key challenges in cell viability and cytotoxicity assays, focusing on the practical application of Vitamin C (CAS 50-81-7, SKU B2064) from APExBIO. Through scenario-driven Q&A, we highlight how high-purity, well-characterized ascorbic acid enhances data reliability, protocol reproducibility, and workflow efficiency for biomedical researchers.

• Reversine: Practical Use as an Aurora Kinase Inhibitor in Ca

  2026-08-06

  Reversine is a small molecule Aurora kinase inhibitor widely applied in studies of mitotic checkpoint control and cancer cell proliferation. This reagent is optimal for in vitro and in vivo protocols examining Aurora kinase signaling and apoptosis induction in cancer cells, especially in cervical cancer models. It should not be used for diagnostic, therapeutic, or clinical purposes.

• SHC-1 Inhibition Enhances CFTR Membrane Abundance in Epithel

  2026-08-06

  This study demonstrates that SHC-1 inhibitors can modulate the plasma membrane abundance of the CFTR chloride channel via the MAPK signaling pathway in epithelial cells. The findings clarify cell-type-specific regulation of CFTR trafficking, informing future strategies for cystic fibrosis and secretory disease research.

• CDC42 Regulates Intestinal Stem Cell Fate via YAP-EGF-mTOR A

  2026-08-05

  Zhang et al. uncover how CDC42-mediated epithelial polarity directs the balance between intestinal stem cells and transit amplifying cells through a YAP-EGF-mTOR signaling pathway, independent of canonical Wnt input. These findings clarify the molecular logic of epithelial homeostasis and suggest new research targets for gastrointestinal biology.

• Merimepodib (VX-497): IMPDH Inhibition for Antiviral & Immun

  2026-08-05

  Merimepodib (VX-497) is a selective, orally bioavailable IMPDH inhibitor with demonstrated efficacy as an antiviral, immunosuppressive, and cancer research agent. It disrupts guanine nucleotide biosynthesis, impairing viral replication and lymphocyte proliferation. Benchmarked in both in vitro and in vivo models, Merimepodib’s specificity and potency are supported by diverse, verifiable data.

• ZIF8 Nanotheranostics for Ultrasound-Guided TNBC Therapy

  2026-08-04

  Li et al. introduce a folic acid-PEG-modified ZIF8 nanoplatform delivering ciprofloxacin for targeted, ultrasound-guided, and synergistic therapy in triple-negative breast cancer (TNBC). The platform integrates pH-responsive drug release, sonodynamic therapy, chemotherapy, and immune activation, presenting a promising strategy to address current TNBC treatment limitations.

• GS967: Cardiac Late Sodium Current Inhibitor for Arrhythmia

  2026-08-04

  GS967 delivers unparalleled selectivity and potency as a cardiac late sodium current inhibitor, enabling precise modeling of arrhythmia mechanisms in both aging and disease. This guide translates the latest mechanistic findings into actionable workflows and troubleshooting strategies, empowering researchers to enhance reproducibility and insight in cardiac electrophysiology studies.

449 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page